Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised to $11.00 at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON – Get a Free Report) had its price target boosted by equities researchers at HC Wainwright from $9.00 to $11.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 59.19% from the company’s current price.

Eton Pharmaceuticals stock performance

Shares of ETON stock opened at $6.91 on Friday. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $6.92. The company’s 50-day simple moving average is $4.57 and its 200-day simple moving average is $3.88. The stock has a market cap of $177.52 million, a price-to-earnings ratio of 172.75 and a beta of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.05). The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $10.00 million. Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%. As a group, research analysts forecast that Eton Pharmaceuticals will post -0.15 EPS for the current year.

Insider buying and selling at Eton Pharmaceuticals

In other news, majority shareholder Opaleye Management Inc. acquired 57,500 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $4.65 per share, for a total transaction of $267,375.00. Following the completion of the purchase, the insider now owns 2,660,000 shares of the company’s stock, valued at $12,369,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this link. 14.89% of shares are owned by company insiders.

Institutional inputs and outputs

Hedge funds have recently made changes to their positions in the stock. Westside Investment Management Inc. boosted its holdings in Eton Pharmaceuticals by 1.9% in the first quarter. Westside Investment Management Inc. now owns 573,960 shares of the company’s stock worth $2,152,000 after purchasing an additional 10,850 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after purchasing an additional 18,898 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares in the last quarter. Opaleye Management Inc. boosted its holdings in Eton Pharmaceuticals by 4.1% during the fourth quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock worth $11,081,000 after buying an additional 99,617 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals in the second quarter valued at about $362,000. Institutional investors and hedge funds own 27.86% of the company’s shares.

About Eton Pharmaceuticals

(Get a free report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development, acquisition and commercialization of pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenal insufficiency in children under 17; Carglumic acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase deficiency; Betaine anhydrous for the treatment of homocystinuria; and nitisinone for the treatment of tyrosinemia type 1.

See Also

Get news and ratings for Eton Pharmaceuticals daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eton Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.